According to a previously
described flow cytometry protocol, cellular binding activity of Sn-mAbs
and 211At-mAbs was evaluated 6 days after 211At-labeling.29 (link)Using a previously
described in vitro binding assay with minor modifications,3 (link) we evaluated the binding activity of 211At-mAbs the day after labeling. In brief, serially diluted OE19 or
NUGC-3 cells in PBS containing 0.1% bovine serum albumin (BSA) and
2 mM ethylenediaminetetraacetic acid (EDTA) (BE-PBS) were incubated
for 30 min on ice with 5 kBq of 211At-mAbs. Then, samples
were washed three times with BE-PBS. The radioactivity bound to the
cells was counted using a gamma counter (2480 Wizard2;
PerkinElmer, Waltham, MA, USA), and the percentage of cellular binding
was calculated by dividing the radioactivity bound to the cells by
the initially added radioactivity. The immunoreactivity of 211At-mAbs was determined according to the method of Lindmo et al.34 (link)
described flow cytometry protocol, cellular binding activity of Sn-mAbs
and 211At-mAbs was evaluated 6 days after 211At-labeling.29 (link)Using a previously
described in vitro binding assay with minor modifications,3 (link) we evaluated the binding activity of 211At-mAbs the day after labeling. In brief, serially diluted OE19 or
NUGC-3 cells in PBS containing 0.1% bovine serum albumin (BSA) and
2 mM ethylenediaminetetraacetic acid (EDTA) (BE-PBS) were incubated
for 30 min on ice with 5 kBq of 211At-mAbs. Then, samples
were washed three times with BE-PBS. The radioactivity bound to the
cells was counted using a gamma counter (2480 Wizard2;
PerkinElmer, Waltham, MA, USA), and the percentage of cellular binding
was calculated by dividing the radioactivity bound to the cells by
the initially added radioactivity. The immunoreactivity of 211At-mAbs was determined according to the method of Lindmo et al.34 (link)
